Shenzhen Kangtai Biological Products (300601.SZ) issued a profit warning, with an estimated net profit for the year 2024 expected to be between 190 million and 270 million yuan, a year-on-year decrease of 77.94% to 68.65%.
Kangtai Biological (300601.SZ) released its performance forecast for 2024. The company expects its net profit for 2024 to be...
Shenzhen Kangtai Biological Products (300601.SZ) issued a performance forecast for 2024, with the company expecting a net profit attributable to shareholders of the listed company of 190 million to 270 million yuan, a year-on-year decrease of 77.94% to 68.65%; after deducting non-recurring gains and losses, the net profit is expected to be 205 million to 290 million yuan, a year-on-year decrease of 71.61% to 59.84%.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
